A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2017-08-25
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Phase 1 study of orally administered CB-5083 in adult
subjects with advanced metastatic solid tumors. The study will be conducted in 2 parts: an
initial Dose Escalation Phase (Phase 1a) of CB-5083 in subjects with advanced metastatic
solid tumors who have progressed or are non-responsive to available therapies and for which
no standard therapy exists, followed by a Dose Expansion Phase (Phase 1b) which will include
1 to 4 arms: one arm in subjects with RAS mutated mCRC; optionally, at sponsors discretion, 3
additional arms may be added for subjects with advanced RCC, advanced pNET, or solid tumors
with mutations in the RAS-MAPK pathway.